Boston Scientific (BSX) Gains from Investment Securities (2020 - 2026)

Boston Scientific (BSX) has 7 years of Gains from Investment Securities data on file, last reported at -$30.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities fell 700.0% year-over-year to -$30.0 million; the trailing twelve-month figure through Mar 2026 stood at -$17.0 million (changed 0.0% YoY), and the FY2025 full-year result was $18.0 million, up 460.0% from the prior year.
• Gains from Investment Securities eased to -$30.0 million in Q1 2026, from $7.0 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $36.0 million in Q2 2022 to a low of -$33.0 million in Q4 2022.
• A 5-year average of $4.5 million and a median of $11.0 million in 2025 frame the typical range for Gains from Investment Securities.
• Across the five-year window, Gains from Investment Securities surged 800.0% in 2025 and tumbled 700.0% in 2026, its largest moves.
• Tracing BSX's Gains from Investment Securities over 5 years: stood at -$33.0 million in 2022, then soared by 145.45% to $15.0 million in 2023, then plunged by 106.67% to -$1.0 million in 2024, then surged by 800.0% to $7.0 million in 2025, then slumped by 528.57% to -$30.0 million in 2026.
• Business Quant data shows BSX's Gains from Investment Securities at -$30.0 million in Q1 2026, $7.0 million in Q4 2025, and $11.0 million in Q3 2025.